Treatment of Ovarian Cancer in Malignant Sex Cord-Stromal Tumor of the Ovary
Malignant sex cord-stromal tumors of the ovary represent a distinct histologic subtype of ovarian cancer. Management decisions in this setting are guided by surgical staging and risk stratification.
Clinical scenario
This protocol applies to patients with ovarian cancer arising from a malignant sex cord-stromal tumor of the ovary. Stage and risk category at diagnosis are central to determining the appropriate adjuvant management strategy.
Treatment approach (partial)
Adjuvant management depends on disease stage and risk classification. For certain stage and risk categories, observation alone may be appropriate, while others may warrant consideration of platinum-based chemotherapy. The complete staging-based algorithm and preferred regimen options are available in the full protocol.
References
- Malignant sex cord-stromal tumors
- Consider platinum-based chemotherapy (category 2B)
- Platinum-based chemotherapy
- Acceptable options include carboplatin/paclitaxel (preferred), EP (etoposide/cisplatin), or BEP (bleomycin/etoposide/cisplatin) (category 2B).
- RT for limited disease (category 2B)
View source ↗